Noteworthy OCUL Put and Call Options Set for February 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: NASDAQ.COM
Put Contract Overview: The $11.00 put contract for OCUL has a bid of 30 cents, allowing investors to buy shares at $11.00 while collecting a premium, effectively lowering the cost basis to $10.70. There is a 72% chance the contract may expire worthless, offering a potential 2.73% return on cash commitment.
Call Contract Overview: The $14.00 call contract has a bid of $2.30, allowing investors to sell shares at that price if they buy at $12.37. This could yield a total return of 31.77% if exercised, with a 44% chance of expiring worthless, which would still allow investors to keep their shares and the premium.
Volatility Insights: The implied volatility for the put contract is 146%, while the call contract's implied volatility is 135%. The actual trailing twelve-month volatility is calculated at 67%, indicating a significant difference between implied and actual market volatility.
YieldBoost Concept: The potential returns from both the put and call contracts are referred to as "YieldBoost," with the put offering a 15.80% annualized return if it expires worthless, and the call providing a 107.72% annualized return under similar conditions.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on OCUL
Wall Street analysts forecast OCUL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCUL is 23.43 USD with a low forecast of 20.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.280
Low
20.00
Averages
23.43
High
31.00
Current: 10.280
Low
20.00
Averages
23.43
High
31.00
About OCUL
Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company. AXPAXLI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases and conditions of the eye.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sanofi Prepares to Raise Bid for Ocular Therapeutix to $16 per Share
- Bid Increase: Sanofi is preparing to raise its acquisition bid for Ocular Therapeutix to $16 per share after the initial offer was rejected, indicating strong interest that could further enhance Ocular's market valuation.
- Stock Surge: Ocular Therapeutix shares surged approximately 21% in premarket trading, rising from $10.50 to $11.20, reflecting positive market sentiment regarding the acquisition news and investor optimism about the company's future.
- Market Potential: Ocular's tyrosine kinase inhibitor Axpaxli is in late-stage development for wet age-related macular degeneration (AMD), with topline data from the SOL-1 study expected in Q1 2026, potentially providing Sanofi with an entry into this lucrative market.
- Mixed Technical Indicators: Currently, Ocular's stock is trading 1.7% above its 20-day simple moving average but 0.7% below its 50-day moving average, indicating mixed short-term technical signals, although shares have increased approximately 48.34% over the past year, suggesting cautious optimism among investors.
Continue Reading
Boston Scientific Acquires Penumbra at $374 per Share
- Acquisition Deal: Boston Scientific has agreed to acquire Penumbra at $374 per share, valuing the transaction at approximately $14.5 billion, indicating strong interest in the medical device market and expected to enhance Boston Scientific's product portfolio and market share.
- Shareholder Options: Penumbra shareholders can choose between cash or Boston Scientific stock, with an overall proration of about 73% cash and 27% equity, which may attract more investor participation and enhance shareholder satisfaction.
- Strong Performance: Penumbra's preliminary fourth-quarter results exceeded expectations, with shares rising 12.1% to $351.25 on Thursday, reflecting market confidence in its future growth potential and likely boosting investor sentiment further.
- Market Reaction: The acquisition news significantly boosted Penumbra's stock price, demonstrating a positive market response to M&A activities in the healthcare sector, which may also trigger similar acquisition activities among other related companies, further energizing the market.
Continue Reading